Overview

* Castle Biosciences Q3 2025 revenue of $83 mln beats analyst expectations

* Company reports Q3 2025 net loss of $0.5 mln, down from net income in Q3 2024

Outlook

* Castle Biosciences ( CSTL ) raises full-year 2025 revenue guidance to $327-335 mln

* Company launches AdvanceAD-Tx test for atopic dermatitis treatment decisions

Result Drivers

* CORE TESTS GROWTH - DecisionDx-Melanoma and TissueCypher test reports increased significantly, driving revenue growth

* COVERAGE IMPACT - Novitas LCD and discontinuation of IDgenetix affected revenue and test report volumes

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $83.04 $71.20

Revenue mln mln (8

Analysts

)

Q3 Net -$501,00

Income 0

Q3 $89.84

Operatin mln

g

Expenses

Q3 -$6.80

Operatin mln

g Income

Q3 -$386,00

Pretax 0

Profit

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

* Wall Street's median 12-month price target for Castle Biosciences Inc ( CSTL ) is $35.50, about 28.2% above its October 31 closing price of $25.50

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)